敗血症診断市場：技術別、製品別、病原体別、検査タイプ別、地域別、2024年～2031年

敗血症診断市場評価、2024年～2031年

敗血症診断の市場規模は2023年に6億8,720万米ドル、予測期間中のCAGRは8.3%で、2031年までに14億430万米ドルの成長が予測されます。世界中で敗血症患者が増加していることと、この疾患の重症度に対する認識が高まっていることが、敗血症診断に対する需要を促進しています。分子診断やバイオマーカーなどの診断技術の急速な進歩により、早期発見と治療が促進され、患者の転帰が改善されています。さらに、特に先進国では、ヘルスケアシステムにおける政府プログラムや資金援助が、最新の診断機器の使用を促進しています。ヘルスケア関連感染の増加は、正確かつ迅速な敗血症診断の必要性を高めています。

敗血症診断市場定義/概要

敗血症診断とは、感染に対する身体の過剰反応によって引き起こされる生命を脅かす状態である敗血症を特定するために使用される手順や技術を指します。早期診断は生存率を高めるために極めて重要です。血液検査、分子診断、バイオマーカー同定はすべて、病原体や体内の炎症反応を検出するために用いられる診断技術です。これらの検査により、ヘルスケア従事者は敗血症を迅速に発見することができ、迅速な治療が可能となり、介入の遅れによる臓器不全や死亡などの合併症を減少させることができます。

これらの診断法は、バイオマーカー、感染症、免疫反応を分析し、敗血症の有無を判定します。迅速かつ正確な診断により、タイムリーな介入が可能となり、臓器不全の可能性を減らし、患者の生存率を高めることができます。敗血症診断は病院、検査室、ポイントオブケアの現場で活用され、臨床判断の指針、患者の状態のモニタリング、治療アプローチの最適化に役立ち、より良いヘルスケア転帰をもたらします。

敗血症診断の将来は、より迅速で正確な個別化診断ツールの開発にあります。人工知能、機械学習、バイオマーカー研究の進歩は、敗血症の早期発見を可能にし、患者の転帰を改善します。ポイントオブケア検査やリアルタイムモニタリングシステムは、クリティカルケアの現場で即座に結果を提供するものとして、より広く普及することが期待されます。

慢性疾患と院内感染は、敗血症診断市場における高度診断ツールの需要にどのように影響するか？

慢性疾患と院内感染は、敗血症診断市場における高度診断機器の需要に大きな影響を与えます。糖尿病、がん、呼吸器疾患などの慢性疾患患者は、敗血症に進行する可能性のある感染症にかかりやすいです。これらの慢性疾患の世界の頻度が高まるにつれ、ヘルスケアプロバイダーは敗血症を早期に発見するため、より迅速で正確な診断技術を求めています。迅速な診断に対するこの重要なニーズが、病原体の検出とモニタリングを改善する新技術への投資を後押ししています。

さらに、院内感染（HAI）はヘルスケア環境における大きな関心事となっており、その結果、入院患者における敗血症の発生率が増加しています。HAI管理の複雑さには、原因菌とその抗生物質感受性を迅速に特定できる高度な診断技術の導入が関わっています。ヘルスケアシステムが患者の転帰を改善し、敗血症に関連する死亡率を減少させることに取り組む中、診断ソリューションの改善に対する需要は増加し、敗血症診断市場における迅速な介入と集中的な治療薬の必要性が強調されるであろう。

先進診断技術の高コストは敗血症診断市場における普及の抑制要因か？

最新の診断技術は高コストであるため、敗血症診断業界、特に資源に乏しいヘルスケア環境での普及には大きな制約があります。特に発展途上国では、多くの病院や診療所が財政的な制約に直面しており、最先端の診断技術の導入が制限されています。このような病院では、敗血症の特定を旧来の方法に頼ることが多いが、この方法は効果が低く、時間がかかるため、患者の転帰に影響を及ぼす可能性があります。その結果、改良された診断法の潜在的な利点が十分に活用されないまま、敗血症による死亡率の増加につながっています。

さらに、この先端技術の導入と維持に伴う費用負担は、ヘルスケア提供者が重要な支出を行うことを躊躇させる可能性があります。このような制約は、継続的な訓練と支援が必要なため、全体的なコストが増大することによってさらに悪化します。高コストの診断薬への投資を控えることは、過小診断と治療の遅れのループにつながり、敗血症診断セクターの成長を阻害する可能性があります。

目次

第1章 世界の敗血症診断市場のイントロダクション

• 市場のイントロダクション
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の敗血症診断市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 敗血症診断の世界市場：技術別

• 概要
• 微生物学
• 分子診断
• 免疫測定法

第6章 敗血症診断の世界市場：製品別

• 概要
• アッセイと試薬
• 血液培養培地
• 器具

第7章 敗血症診断の世界市場：病原体別

• 概要
• 真菌性敗血症
• 細菌性敗血症

第8章 敗血症診断の世界市場：検査タイプ別

• 概要
• ラボ検査
• ポイントオブケア検査

第9章 敗血症診断の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界の敗血症診断市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第11章 企業プロファイル

• Abbott Laboratories
• Becton, Dickinson and Company
• BioMerieux
• Luminex
• Danaher
• T2 Biosystems
• Thermo Fisher Scientific
• Roche Diagnostics
• Bruker
• Immunexpress

第12章 主な発展

• 製品の上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第13章 付録

• 関連調査

Sepsis Diagnostics Market Valuation - 2024-2031

The sepsis diagnostics market size was valued at USD 687.2 Million in 2023 and is projected to grow 1404.3 Million by 2031, exhibiting a CAGR of 8.3% during the forecast period. Rising sepsis cases around the world combined with increased awareness of the condition's severity are driving demand for sepsis diagnostics. Rapid advances in diagnostic technology such as molecular diagnostics and biomarkers are accelerating early identification and treatment, resulting in better patient outcomes. Furthermore, government programs and funding in healthcare systems, particularly in developed countries, promote the use of modern diagnostic equipment. The increasing prevalence of healthcare-associated infections is exacerbating the need for accurate and rapid sepsis diagnosis.

Sepsis Diagnostics Market: Definition/ Overview

Sepsis diagnostics refers to the procedures and technologies used to identify sepsis, which is a life-threatening condition caused by the body's overreaction to infection. Early diagnosis is crucial for increasing survival rates. Blood testing, molecular diagnostics, and biomarker identification are all diagnostic techniques used to detect pathogens and inflammatory responses in the body. These tests enable healthcare practitioners to detect sepsis rapidly allowing for immediate treatment and decreasing complications such as organ failure or death caused by delayed intervention.

These diagnostics analyze biomarkers, infections, and immune responses to determine the existence of sepsis. Rapid and precise diagnosis allows for timely intervention which reduces the chance of organ failure and increases patient survival rates. Sepsis diagnostics are utilized in hospitals, laboratories, and point-of-care settings to help guide clinical decisions, monitor patient states, and optimize treatment approaches resulting in better healthcare outcomes.

The future of sepsis diagnostics lies in the development of faster, more accurate, and personalized diagnostic tools. Advancements in artificial intelligence, machine learning, and biomarker research will enable earlier detection of sepsis, improving patient outcomes. Point-of-care testing and real-time monitoring systems are expected to become more widespread offering immediate results in critical care settings.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How do Chronic Diseases and Hospital-Acquired Infections Influence the Demand for Advanced Diagnostic Tools in the Sepsis Diagnostics Market?

Chronic diseases and hospital-acquired infections have a substantial impact on the demand for enhanced diagnostic instruments in the sepsis diagnostics market. Patients with chronic disorders such as diabetes, cancer, and respiratory problems are more vulnerable to infections which can progress to sepsis. As the global frequency of these chronic diseases rises, healthcare providers are looking for faster and more accurate diagnostic techniques to detect sepsis in its early stages. This important need for fast diagnosis drives investments in new technologies that improve pathogen detection and monitoring.

Furthermore, hospital-acquired infections (HAIs) are becoming a major concern in healthcare settings, resulting in the increasing incidence of sepsis among hospitalized patients. The complexity of HAI management involves the deployment of sophisticated diagnostic technologies capable of swiftly identifying the causative agents and their antibiotic susceptibility. As healthcare systems work to improve patient outcomes and reduce sepsis-related mortality, the demand for improved diagnostic solutions will increase, emphasizing the necessity of prompt intervention and focused therapeutics in the sepsis diagnostics market.

How Does the High Cost of Advanced Diagnostic Technologies Serve as a Restraint to Widespread Adoption in the Sepsis Diagnostics Market?

The high cost of modern diagnostic technologies severely limits widespread use in the sepsis diagnostics industry, especially in resource-constrained healthcare settings. Many hospitals and clinics, particularly in developing countries, confront financial constraints that restrict them from adopting cutting-edge diagnostic technologies. These hospitals frequently rely on older methods for identifying sepsis which can be less effective and slower, affecting patient outcomes. As a result, the potential benefits of improved diagnostics remain underutilized contributing to greater sepsis death rates.

Furthermore, the cost burden associated with deploying and maintaining this advanced technology may discourage healthcare providers from making critical expenditures. This constraint is exacerbated by the requirement for continual training and assistance which increases the overall cost. Reluctance to invest in high-cost diagnostics might lead to a loop of underdiagnosis and delayed treatment impeding growth in the sepsis diagnostics sector.

Category-Wise Acumens

How do Advancements in Blood Culture Technology Improve the Detection of Pathogens in Sepsis Cases?

Blood culture media are dominant in the sepsis diagnostics market primarily due to their crucial role in identifying the pathogens responsible for sepsis. These media facilitate the growth of bacteria and fungi from blood samples enabling accurate and timely diagnosis. The ability to detect a wide range of microorganisms including those that are fastidious or present in low concentrations, makes blood culture a gold standard in sepsis diagnostics. As early detection is vital for effective treatment, the reliability and sensitivity of blood culture media significantly contribute to their prevalence in clinical settings.

Furthermore, advancements in blood culture technology such as automated systems that monitor growth and provide rapid results enhance their effectiveness. Innovations like continuous monitoring and improved sensitivity have expanded their utility in diagnosing sepsis even in challenging cases. As healthcare systems increasingly prioritize early intervention and precise diagnostics to improve patient outcomes, the demand for blood culture media continues to grow solidifying their dominant position in the market.

How Does the Diversity and Evolution of Sepsis-Causing Pathogens Challenge Traditional Diagnostic Methods?

Molecular diagnostics is more dominant in the sepsis diagnostics market due to its ability to provide rapid and accurate identification of pathogens causing sepsis. Unlike traditional culture methods which can take days to yield results, molecular techniques such as polymerase chain reaction (PCR) and next-generation sequencing deliver results in a matter of hours. This speed is crucial for timely treatment decisions, significantly improving patient outcomes and reducing mortality rates associated with sepsis.

Furthermore, molecular diagnostics can detect a wide variety of pathogens including bacteria, viruses, and fungi, in a single test. This extensive detection capability is critical given the diversity and evolution of sepsis-causing pathogens. As healthcare practitioners recognize the value of early intervention, the demand for better diagnostic technologies grows. The growing use of point-of-care testing increases the accessibility and utility of molecular diagnostics in critical care settings cementing its dominance in the sepsis diagnostics market.

Sepsis Diagnostics Market

Report Methodology

Country/Region-wise Acumens

How do Increased Awareness and Education among Healthcare Professionals and Patients Affect the Sepsis Diagnostics Market in the North American Region?

North America dominates the sepsis diagnostics market because of its advanced healthcare infrastructure and large spending on medical research & development. The region is home to many top diagnostic firms and research organizations that promote innovation in sepsis detection methods. This has resulted in the development of cutting-edge treatments like molecular diagnostics and quick testing systems which allow healthcare providers to identify sepsis more effectively and efficiently.

Furthermore, the rising occurrence of sepsis, together with increased awareness among healthcare professionals and patients drives market expansion. The presence of well-established healthcare systems promotes the use of advanced diagnostic technologies which improves patient outcomes. Furthermore, legislative and financing initiatives in North America promote the development and commercialization of novel diagnostic technology. As a result, North America continues to dominate the sepsis diagnostics industry using its strengths in technology, research, and healthcare delivery.

How Does the Developing Healthcare Infrastructure Influence the Adoption of Modern Diagnostic Tools for Sepsis in the Asia-Pacific Region?

Asia Pacific is the fastest-growing area in the sepsis diagnostics market owing to a rapidly growing patient population fuelled by rising infection rates, chronic diseases, and an aging demographic. The region's developing healthcare infrastructure combined with significant government investment in healthcare innovations encourages the use of modern diagnostic tools. As knowledge of sepsis and its serious effects develops, healthcare providers are focussing more on strengthening diagnostic capabilities to ensure timely and successful treatment.

Furthermore, the growth of biotechnology and pharmaceutical companies in countries such as China and India creates a competitive climate for producing sophisticated diagnostics. The increasing demand for point-of-care testing and molecular diagnostics is also propelling expansion in this sector. Furthermore, the rising prevalence of hospital-acquired infections and the necessity for rapid diagnostic solutions in healthcare facilities highlight the importance of effective sepsis diagnostics. These factors combine to position Asia Pacific as a major participant in the global sepsis diagnostics market.

Competitive Landscape

The Sepsis Diagnostics Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the sepsis diagnostics market include:

Abbott Laboratories, Becton Dickinson and Company, BioMerieux, Luminex, Danaher, T2 Biosystems, Thermo Fisher Scientific, Roche Diagnostics, Bruker, Immunexpress.

Latest Developments

In April 2024, The US Food and Drug Administration (FDA) approved Prenosis' AI tool Sepsis ImmunoScore to diagnose sepsis. This authorization, obtained through the De Novo procedure, is the first FDA approval of an AI/machine learning (ML) software as a medical device (SaMD) for sepsis detection and prediction.

In May 2024, Cytovale, a medical diagnostics company, announced the publication of data demonstrating that its sepsis diagnosis tool IntelliSep has a negative predictive value of 97.5 percent. The FDA-approved IntelliSep technology allows for the rapid detection of sepsis in adults who exhibit signs and symptoms of infection by squeezing white blood cells to characterize their reactions to infection.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL SEPSIS DIAGNOSTICS MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL SEPSIS DIAGNOSTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY

• 5.1 Overview
• 5.2 Microbiology
• 5.3 Molecular Diagnostics
• 5.4 Immunoassays

6 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PRODUCT

• 6.1 Overview
• 6.2 Assay and reagents
• 6.3 Blood culture media
• 6.4 Instruments

7 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN

• 7.1 Overview
• 7.2 Fungal sepsis
• 7.3 Bacterial sepsis

8 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TESTING TYPE

• 8.1 Overview
• 8.2 Laboratory Tests
• 8.3 Point-of-care Tests

9 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East & Africa

10 GLOBAL SEPSIS DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Abbott Laboratories
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Becton, Dickinson and Company
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 BioMerieux
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Luminex
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Danaher
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 T2 Biosystems
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Thermo Fisher Scientific
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Roche Diagnostics
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Bruker
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Immunexpress
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 Appendix

• 12.1 Related Research